Last reviewed: May 15, 2026
Last updated: May 15, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
Remedy Meds and Mochi represent two distinct telehealth models for GLP-1 medication access. Remedy Meds focuses on direct-to-consumer telemedicine with rapid provider matching, while Mochi emphasizes comprehensive health coaching alongside medication management. Both platforms have captured significant market share as demand for GLP-1 therapies continues to grow, but their operational philosophies differ substantially.
Choosing between Remedy Meds and Mochi—or exploring additional precision-based options—requires understanding how each platform evaluates patient candidacy, prices medications, and customizes treatment plans. PlexusDx takes a different approach: combining compounded GLP-1 medications from licensed 503A pharmacies with optional genetic testing to support personalized provider conversations rather than algorithmic matching alone.
Remedy Meds vs Mochi: Platform Structure and Clinical Models
Remedy Meds operates as a streamlined telemedicine service connecting patients with licensed providers for rapid GLP-1 evaluation and prescription. The platform prioritizes speed-to-prescription and flexible dosing options, catering to patients seeking efficiency. Mochi takes a more comprehensive health-coaching approach, combining provider consultation with ongoing nutritionist support and behavioral guidance alongside medication management.
Both platforms conduct medical screening before prescribing GLP-1 medications, but their depth of personalization differs. Remedy Meds typically focuses on baseline labs and medical history, while Mochi incorporates lifestyle assessment and ongoing progress tracking. Neither platform currently offers genetic testing to explore predispositions in peptide-response pathways, which represents a clinical gap for patients seeking deeper molecular context.
Pricing, Accessibility, and Out-of-Pocket Cost Structures
Remedy Meds generally charges consultation fees ($99–$150 per visit) plus medication costs, which vary based on pharmacy sourcing and supply chains. Mochi typically bundles provider visits, coaching sessions, and medications into tiered subscription models ($199–$399 monthly), appealing to patients seeking all-in-one pricing transparency. Both platforms work with insurance when possible, but many users pay out-of-pocket for speed and medication selection.
Cost predictability matters significantly for long-term GLP-1 therapy. Mochi's bundled model may offer clarity upfront, while Remedy Meds' visit-based approach allows flexibility if patients pause treatment. PlexusDx compounded semaglutide starts at $149 monthly and compounded tirzepatide at $249 monthly, with optional genetic testing ($99 add-on or $298 standalone) to contextualize medication selection alongside provider guidance.
| Aspect |
Remedy Meds |
Mochi |
PlexusDx Model |
| Consultation Model |
Per-visit ($99–$150) |
Subscription-bundled ($199–$399/mo) |
Provider-directed with optional genetic context |
| Medication Sourcing |
Pharmacy network (brand or generic) |
Proprietary supplier partnerships |
Licensed 503A compounded pharmacies only |
| Personalization |
Medical history + labs |
Lifestyle coaching + labs + coaching |
Genetic testing + provider assessment available |
| Insurance Integration |
Varies by plan |
Partial coverage common |
Direct pharmacy billing; insurance varies |
Provider Eligibility and Medical Screening Standards
Remedy Meds prioritizes rapid provider matching, often connecting patients within hours. Providers assess baseline cardiovascular health, kidney function, diabetes status, and BMI history. The streamlined approach suits patients with straightforward medical profiles but may offer limited depth for those with complex comorbidities or polypharmacy concerns.
Mochi's provider eligibility framework includes more extensive dietary and lifestyle assessment alongside clinical labs, extending evaluation timelines but potentially capturing nuances Remedy Meds might miss. Both platforms exclude patients with personal or family history of medullary thyroid cancer or MEN2 syndrome per GLP-1 safety guidance. PlexusDx providers integrate genetic predisposition data from the Precision Peptide Genetic Test (revealing variants in GIPR, GLP1R, FTO, and MC4R pathways) to contextualize clinical decisions rather than replace traditional screening.
Genetic Testing and Molecular Personalization Context
Neither Remedy Meds nor Mochi currently incorporate genetic testing into their assessment workflows. This means both platforms rely on observable clinical factors, BMI history, and metabolic markers without exploring whether a patient's genetic architecture might predispose them toward stronger or weaker GLP-1 receptor sensitivity, body-weight regulation pathways, or metabolic flexibility.
The Precision Peptide Genetic Test offered by PlexusDx analyzes variants in peptide-pathway genes—GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—to provide context for provider conversations. These predispositions may help inform medication selection and dosing strategy alongside clinical judgment. A patient might discover, for example, that certain genetic variants correlate with enhanced GLP-1R signaling or altered metabolic setpoint, creating a more evidence-informed discussion with their provider about which compounded peptide option to explore.
Safety Monitoring, Adverse Event Management, and Ongoing Support
Remedy Meds typically offers asynchronous message-based follow-up with providers, allowing patients to report side effects or dose concerns without scheduling new visits. Response times vary by provider availability. Mochi's bundled coaching model includes more frequent touchpoints with nutritionists and health coaches who can flag emerging concerns and adjust lifestyle support in real time, though prescription changes still require provider authorization.
Both platforms monitor for known GLP-1 adverse effects: nausea, vomiting, constipation, pancreatitis risk, and thyroid safety concerns. Patients on either platform should report severe abdominal pain, vision changes, or persistent vomiting immediately to their provider or emergency services. PlexusDx compounded medications follow the same safety protocols as branded alternatives; providers should conduct baseline renal function, lipase, and calcitonin assessment before prescribing, with periodic follow-up labs based on clinical judgment.
How PlexusDx Supports a More Personalized Approach
Genetic predispositions in peptide-signaling pathways—such as GLP1R sensitivity or FTO-mediated energy homeostasis variants—may help contextualize why some patients experience robust weight-loss response while others show modest results. The Precision Peptide Genetic Test cannot predict exact medication response, but variants in these pathways can support a more informed conversation between patient and provider about which compounded GLP-1 option to trial first.
PlexusDx's compounded semaglutide and tirzepatide are sourced exclusively from licensed 503A compounding pharmacies—not 503B facilities—ensuring regulatory oversight, sterility, and quality assurance aligned with traditional pharmacy practices. When paired with optional genetic testing, this approach supports precision-informed medication selection alongside standard clinical screening, complementing the rapid-access or coaching-integrated models that Remedy Meds and Mochi provide.
Whether you choose Remedy Meds for speed, Mochi for integrated coaching, or PlexusDx for compounded peptides with genetic context, working with a qualified healthcare provider remains essential. Genetic predisposition data should be interpreted collaboratively—it informs discussion, not diagnosis—and complements, rather than replaces, thorough medical evaluation and ongoing provider monitoring.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is the main difference between Remedy Meds and Mochi?
Remedy Meds emphasizes rapid telemedicine matching and visit-based pricing, while Mochi bundles provider care with ongoing health coaching and nutritionist support in a subscription model. Remedy Meds suits patients prioritizing speed; Mochi appeals to those seeking integrated lifestyle support alongside medication management.
Does Remedy Meds or Mochi offer genetic testing for GLP-1 response?
Neither Remedy Meds nor Mochi currently include genetic testing in their standard assessment. PlexusDx offers the Precision Peptide Genetic Test as an optional add-on to explore predispositions in peptide-pathway variants, supporting more personalized provider conversations about medication selection.
Which platform is more affordable long-term?
Remedy Meds' per-visit model may cost less initially but adds up with frequent provider consultations. Mochi's bundled subscription provides pricing clarity. PlexusDx compounded medications ($149/mo) plus optional genetic testing ($99 add-on) offer direct cost predictability, with savings compared to some branded alternatives.
What safety screening do Remedy Meds and Mochi require?
Both platforms assess baseline labs, cardiovascular health, and kidney function before prescribing. Both exclude patients with personal or family history of medullary thyroid cancer or MEN2 syndrome.
Can genetic testing help me choose between GLP-1 medications?
Yes. The Precision Peptide Genetic Test reveals predispositions in GIPR, GLP1R, FTO, and MC4R pathways that may contextualize how your body processes peptide therapies. This information should be discussed with your provider—it supports informed conversation but does not guarantee outcomes or replace clinical judgment.
What is the difference between PlexusDx compounded medications and branded GLP-1 drugs?
PlexusDx compounded semaglutide and tirzepatide are prepared by licensed 503A pharmacies under regulated conditions, distinct from branded products like Ozempic or Mounjaro.
Related Reading
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Orderly Meds Ozempic: Telemedicine Access, Genetic Fit, and Clinical Alternatives
Ro vs LifeMD: Biomarkers and Genetic Factors in GLP-1 Selection